Stockreport

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy [Yahoo! Finance]

Cytokinetics, Incorporated  (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for aficamten , a next-in-class cardiac myosin inhibitor, for the treatment of obs [Read more]